NCT06465433View on ClinicalTrials.gov

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

August 29, 2027

Study Completion Date

August 29, 2027

Conditions
Hematologic Malignancies
Interventions
DRUG

Tafasitamab

Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.

Trial Locations (5)

31008

COMPLETED

Clinica Universitad de Navarra, Pamplona

09023

RECRUITING

Petz Aladar County Teaching Hospital, Győr

05100

COMPLETED

Hospital S.M. Terni University of Perugia, Terni

06351

RECRUITING

Samsung Medical Center, Seoul

06500

RECRUITING

Gazi University Hospital Gazi University Faculty of Medicine, Ankara

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT06465433 - Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab | Biotech Hunter | Biotech Hunter